Faculty mentor/PI email address
whitecp@rowan.edu
Is your research Teaching and Learning based?
1
Keywords
Alzheimer’s disease, Amyloid PET, Tau biomarkers, Biomarker discordance, Mixed dementia, Alcohol-related cognitive impairment
Date of Presentation
5-6-2026 12:00 AM
Poster Abstract
Alzheimer’s disease (AD) is commonly diagnosed using a combination of clinical evaluation and biomarkers, including amyloid positron emission tomography (PET) imaging and tau protein levels. However, discordant biomarker findings can complicate diagnosis and clinical decision-making. We present a case study of a patient with progressive cognitive decline who demonstrated positive amyloid PET imaging but negative tau biomarkers. The objective of this case report is to demonstrate key diagnostic challenges in Alzheimer’s disease and highlight the need for a comprehensive, multimodal diagnostic approach. This case underscores the limitations of relying on a single biomarker modality and highlights the potential for overlap with other neurocognitive disorders or preclinical stages of AD. A comprehensive approach integrating clinical presentation, neuropsychological testing, imaging, and biomarkers is essential to improve diagnostic accuracy and guide appropriate management.
Disciplines
Medicine and Health Sciences | Mental Disorders | Nervous System Diseases
Included in
When Biomarkers Disagree: Diagnostic Challenges in Alzheimer’s Disease
Alzheimer’s disease (AD) is commonly diagnosed using a combination of clinical evaluation and biomarkers, including amyloid positron emission tomography (PET) imaging and tau protein levels. However, discordant biomarker findings can complicate diagnosis and clinical decision-making. We present a case study of a patient with progressive cognitive decline who demonstrated positive amyloid PET imaging but negative tau biomarkers. The objective of this case report is to demonstrate key diagnostic challenges in Alzheimer’s disease and highlight the need for a comprehensive, multimodal diagnostic approach. This case underscores the limitations of relying on a single biomarker modality and highlights the potential for overlap with other neurocognitive disorders or preclinical stages of AD. A comprehensive approach integrating clinical presentation, neuropsychological testing, imaging, and biomarkers is essential to improve diagnostic accuracy and guide appropriate management.